Bio-Thera Solutions (SHA: 688177) of Guangzhou acquired rights to use drug delivery technologies from London 's Intract Pharma to develop a novel oral mAb treatment for chronic gastrointestinal inflammatory diseases. Intract will receive an undisclosed upfront payment, with potential milestones and royalties on sales. Intract will lead preclinical research of the product, while Bio-Thera will have an option to expand development of the product for multiple GI indications and will be responsible for manufacturing and commercializing any approved products. More details.... Share this with colleagues: // //